Dosing & Uses
Dosage Forms & Strengths
ointment
- 500unit/g
Dermal Infections (Superficial)
Apply ointment qDay-q8hr
Dosage Forms & Strengths
ointment
- 500unit/g
Dermal Infections (Superficial)
Apply ointment qDay-q8hr
Adverse Effects
Frequency Not Defined
Rash
Itching
Pain
Hypersensitivity reaction (rare)
Warnings
Contraindications
Hypersensitivity
Use in eyes or in external ear canal if eardrum perforated
Cautions
Do not use for longer than 1 week unless directed by a clinician
Minor skin irritation, rash, and allergic contact dermatitis or other hypersensitivity reactions reported
Topical anti-infectives are known contact sensitizers
Patients sensitive to bacitracin may also have cross-sensitivity to polymyxin B
Serious hypersensitivity reactions, including anaphylaxis, reported rarely following topical application to skin
Consider that patients allergic to bacitracin may have delayed cell-mediated contact dermatitis reactions or immediate IgE-mediated (eg, anaphylactic) reactions to the drug
Prolonged use of topical anti-infectives may promote bacterial resistance and should be avoided; overgrowth of nonsusceptible organisms, including fungi, may occur
If itching, burning, rash, or any other signs of sensitivity or allergic reaction occur, discontinue use and consult a clinician
Pregnancy & Lactation
Pregnancy
Some manufacturers advise pregnant patients to consult a clinician before using topical preparations containing this drug
Lactation
Not known whether topical bacitracin is distributed in milk
Some manufacturers advise breastfeeding women to consult a clinician before using topical preparations containing this drug
Some experts consider this drug compatible with nursing
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inhibits bacterial cell wall synthesis, by preventing the incorporation of mucopeptides into the growing cell wall
Absorption
Not substantially absorbed from intact or denuded skin, wounds, or mucous membranes
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() | |
bacitracin zinc topical - | 500 unit/gram ointment | ![]() |
Copyright © 2010 First DataBank, Inc.